Skip to content

Abstract 18075: Cardiovascular Events and Mortality After KRAS Inhibitor Therapy Discontinuation in Patients with Non-Small Cell Lung Cancer

Nov 2026 · Circulation · 0 citations

Abstract

Background: KRAS inhibitors, including Sotorasib and Adagrasib, have expanded treatment options for patients with KRAS-mutated non small cell lung cancer (NSCLC). However, cardiovascular outcomes after KRAS inhibitor initiation remain poorly characterized. Hypothesis: We hypothesized that cardiovascular events are common after KRAS inhibitor therapy and that KRAS inhibitor discontinuation is associated with increased risk of adverse clinical outcomes. Methods: We performed a retrospective cohort study of patients with NSCLC treated with sotorasib or adagrasib identified through electronic medical record search. The primary outcomes were all-cause mortality and major adverse cardiovascular events (MACE), defined as heart failure, stroke, myocardial infarction, or venous thromboembolism/pulmonary embolism. Secondary outcomes included individual cardiovascular events. Baseline characteristics and outcomes were compared according to KRAS inhibitor discontinuation status. Multivariable time-dependent Cox regression was used to evaluate the association between KRAS inhibitor discontinuation and outcomes, adjusting for age at KRAS inhibitor initiation and sex. Results: The cohort included 167 patients with NSCLC treated with KRAS inhibitors. Median age at KRAS inhibitor initiation was 68.3 years, and 106 patients were female. Cardiovascular comorbidities were common; the 1-year cumulative incidence was 49% for mortality, 30% for heart failure, 11% for stroke, 9% for myocardial infarction, 20% for VTE/PE, and 49% for MACE. KRAS inhibitor discontinuation occurred in 45 patients. In multivariable time-dependent Cox models, KRAS inhibitor discontinuation was associated with increased risk of all-cause mortality (HR 2.43, 95% CI 1.57-3.76, P<.001), heart failure (HR 2.74, 95% CI 1.14-6.58, P=.024), stroke (HR 4.32, 95% CI 1.18-15.8, P=.027), and MACE (HR 2.36, 95% CI 1.21-4.62, P=.012). The association with VTE/PE was not statistically significant. Conclusions: In this cohort of patients with NSCLC treated with KRAS inhibitors, mortality and cardiovascular events were frequent. Compared with continued KRAS inhibitor therapy, discontinuation was independently associated with higher risk of mortality, heart failure, stroke, and MACE. These findings highlight the need for closer cardiovascular surveillance in patients receiving KRAS inhibitor therapy and support further investigation into cardiotoxicity, cancer progression, and treatment discontinuation as interrelated markers of adverse outcomes.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.